<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309385</url>
  </required_header>
  <id_info>
    <org_study_id>DSPV-201</org_study_id>
    <secondary_id>R44EY014772</secondary_id>
    <nct_id>NCT02309385</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis</brief_title>
  <official_title>A Randomized, Parallel Group, Double-masked, Active-controlled Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of Dexamethasone Sodium Phosphate Visulex System for the Treatment of Non-infectious Anterior Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aciont Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Aciont Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy, safety, and tolerability of
      dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in
      patients with acute anterior uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, parallel group, double-masked, active- controlled study.
      Subjects will be enrolled and randomized to either 8 % or 15% DSP-Visulex with placebo drops
      or Vehicle-Visulex (V-Visulex) with prednisolone acetate 1% eye drops. All subjects will
      receive concomitant treatment with cyclopentolate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">March 3, 2017</completion_date>
  <primary_completion_date type="Actual">March 3, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with anterior chamber cell ACC grade of zero</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-emergent adverse events</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with no uveitis symptoms</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement in visual acuity</measure>
    <time_frame>29 days</time_frame>
    <description>Change in ETDRS letter score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anterior chamber cell (ACC) grade</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anterior chamber cell (ACC) grade</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anterior chamber cell (ACC) grade</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with anterior chamber cell ACC grade of zero</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with anterior chamber cell ACC grade of zero</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Non-Infectious Anterior Uveitis</condition>
  <arm_group>
    <arm_group_label>8% DSP-Visulex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15% DSP-Visulex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pred Forte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate (1%) eye drops and vehicle - Visulex in the affected eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8% Dexamethasone Sodium Phosphate - Visulex</intervention_name>
    <arm_group_label>8% DSP-Visulex</arm_group_label>
    <other_name>8% DSP- Visulex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15% Dexamethasone Sodium Phosphate - Visulex</intervention_name>
    <arm_group_label>15% DSP-Visulex</arm_group_label>
    <other_name>8% DSP- Visulex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate (1%) Eye Drops</intervention_name>
    <arm_group_label>Pred Forte</arm_group_label>
    <other_name>Pred Forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-infectious anterior uveitis

        Exclusion Criteria:

          -  lntraocular pressure &gt; 25mm Hg OU.

          -  Previous occurrence of an acute episode of anterior uveitis in affected eye(s) within
             4 weeks prior to Visit 1.

          -  Historical or active intermediate or posterior uveitis in affected eye(s).

          -  Clear systemic causes of uveitis that may require or have required systemic treatment

          -  Uveitis suspected to have resulted from recent surgery or trauma.

          -  Use of ocular medication of any kind in affected eye(s) more than 2 days prior to
             Visit 1, excluding artificial tears, topical allergy medications, eyelid scrubs.

          -  Current use, or anticipated initiation during the study, of a corticosteroid or an
             immunosuppressant agent by any route (oral, inhaled, ocular, dermal). Current stable
             use is allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William I Higuchi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aciont Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye Research and Surgery Institution (MERSI)</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye, Ear, Nose, and Throat Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bergstrom Eye Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B-Berger and Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina and Uveitis Consultants of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moran Eye Center, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011 Jan 5;52(1):80-6. doi: 10.1167/iovs.10-5285.</citation>
    <PMID>20702826</PMID>
  </reference>
  <reference>
    <citation>Czock D, Keller F, Rasche FM, HÃ¤ussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. Review.</citation>
    <PMID>15634032</PMID>
  </reference>
  <reference>
    <citation>Cunningham ET Jr, Wender JD. Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol. 2010 Aug;45(4):352-8. doi: 10.3129/i10-081.</citation>
    <PMID>20648092</PMID>
  </reference>
  <reference>
    <citation>Gan IM, Ugahary LC, van Dissel JT, Feron E, Peperkamp E, Veckeneer M, Mulder PG, Platenkamp GJ, van Meurs JC. Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefes Arch Clin Exp Ophthalmol. 2005 Dec;243(12):1200-5. Epub 2005 Oct 19.</citation>
    <PMID>16235062</PMID>
  </reference>
  <reference>
    <citation>GORDON DM. Use of dexamethasone in eye disease. J Am Med Assoc. 1960 Jan 23;172:311-2.</citation>
    <PMID>13851186</PMID>
  </reference>
  <reference>
    <citation>Miller DJ, Li SK, Tuitupou AL, Kochambilli RP, Papangkorn K, Mix DC Jr, Higuchi WI, Higuchi JW. Passive and oxymetazoline-enhanced delivery with a lens device: pharmacokinetics and efficacy studies with rabbits. J Ocul Pharmacol Ther. 2008 Aug;24(4):385-91. doi: 10.1089/jop.2007.0116.</citation>
    <PMID>18665810</PMID>
  </reference>
  <reference>
    <citation>Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005 Oct 20;353(16):1711-23. Review.</citation>
    <PMID>16236742</PMID>
  </reference>
  <reference>
    <citation>Rohdewald P, MÃ¶llmann H, Barth J, Rehder J, Derendorf H. Pharmacokinetics of dexamethasone and its phosphate ester. Biopharm Drug Dispos. 1987 May-Jun;8(3):205-12.</citation>
    <PMID>3593899</PMID>
  </reference>
  <reference>
    <citation>Weijtens O, Feron EJ, Schoemaker RC, Cohen AF, Lentjes EG, Romijn FP, van Meurs JC. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999 Aug;128(2):192-7.</citation>
    <PMID>10458175</PMID>
  </reference>
  <reference>
    <citation>Weijtens O, Schoemaker RC, Cohen AF, Romijn FP, Lentjes EG, van Rooij J, van Meurs JC. Dexamethasone concentration in vitreous and serum after oral administration. Am J Ophthalmol. 1998 May;125(5):673-9.</citation>
    <PMID>9625551</PMID>
  </reference>
  <reference>
    <citation>Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology. 2002 Oct;109(10):1887-91.</citation>
    <PMID>12359610</PMID>
  </reference>
  <reference>
    <citation>Weijtens O, van der Sluijs FA, Schoemaker RC, Lentjes EG, Cohen AF, Romijn FP, van Meurs JC. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol. 1997 Mar;123(3):358-63.</citation>
    <PMID>9063245</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveitis</keyword>
  <keyword>acute uveitis</keyword>
  <keyword>anterior uveitis</keyword>
  <keyword>dexamethasone sodium phosphate</keyword>
  <keyword>non-infectious uveitis</keyword>
  <keyword>DSP-Visulex</keyword>
  <keyword>Aciont</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Anterior</mesh_term>
    <mesh_term>Iridocyclitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

